Introduction
Kaposi's sarcoma (KS) is the most common cancer diagnosed among people with HIV in the United States (1) and occurs most frequently among those who are immunodeficient (2) . The incidence of KS has been greatly influence by trends in the AIDS epidemic; incidence increased through the 1980s as the AIDS epidemic spread and incidence rates declined dramatically once highly active antiretroviral therapy (HAART) was introduced in 1996 as a treatment (3) (4) (5) .
In addition to being a treatment for HIV, HAART has been shown to cause regression of KS itself (6, 7) and is an essential, often exclusive, treatment for this cancer (8, 9) . Recent reports document the emergence of racial disparities in Kaposi's sarcoma incidence and HIV-related mortality in the United States since the advent of HAART (3, 10) . However, no known studies have explored if these disparities are reflected in survival after diagnosis with Kaposi's sarcoma. Thus, the aim of this study is to examine trends in KS survival by race from the beginning of the HIV epidemic through the introduction of HAART.
Methods

Population
The population-based incidence and survival data from the Surveillance, Epidemiology, and End Results (SEER) nine area public-use database (Connecticut, Detroit, Atlanta, San Francisco, Seattle, Iowa, Utah, New Mexico, and Hawaii) was utilized for this study. Details on the SEER program are published elsewhere (11) . Kaposi Sarcoma cases were coded according to the International Classification of Disease-Oncology, 2 nd Edition (ICD-O-2) as those with a histology code of 9140. From 1980 to 2004 13,682 cases of Kaposi sarcoma were reported. We excluded 213 people whose cancer were ascertained from autopsy or death certificate, 503 people for whom KS was not the first cancer, 370 people with 'other' race, and 125 for whom we lacked information on race. Additionally, because SEER data do not contain information on HIV/AIDS status and non-AIDS related Kaposi's sarcoma tends to occur in the elderly (12) , those 65 years or older (n=745) were also excluded. Our analytic dataset was comprised of 11, 726 individuals and follow-up ended on December 31, 2007 (13) .
The AIDS Clinical Trials Group (ACTG) staging criteria was utilized for tumor risk classification. Those patients with single or multiple skin lesions were classified as having good tumor risk (T 0 ). Those patients with lesions on the mucosa (e.g. oral cavity, anus, rectum, vagina, vulva) or visceral organs (e.g. pulmonary, gastrointestinal tract, spleen, other) alone or in combination with lesions in other areas were considered to have poor tumor risk (T 1 ). Those patients with multiple lesions of non-specific location or unknown number and location of tumors (n=4688) were classified as having unknown tumor risk. The ACTG system classifies single oral tumors differently according to their nodularity and exact location. Because SEER data do not contain this information and there was the possibility of misclassification, we opted to minimize heterogeneity in the low risk group and categorized these tumors as high risk (n=277). An assessment of extent of immunodeficiency or systemic illness is not possible using SEER data, thus we were not able to assess survival according to these factors.
Covariates
Author manuscripts have been peer reviewed and accepted for publication but Analysis SEER defined cause-specific mortality was the endpoint of interest for these analyses. This includes mortality due to Kaposi's sarcoma, HIV/AIDS, and several other cancer types. Details on how this classification is constructed is described elsewhere (17) .
Differences in the distribution of covariates according to race were assessed by conducting two-sided Chi-square tests of association. We compared median survival times using logrank tests to assess absolute survival differences and calculated what we will refer to as the median survival ratio (MSR=median survival among white patients/median survival among black patients) to assess survival differences on the ratio scale. Univariate and multivariate Cox proportional hazards models were constructed to assess the influence of covariates on racial differences in 5-year survival (follow-up for those diagnosed in 2003 and 2004, 2.4% of study population, was ended at 3-and 4-years respectively). There 7 were very few women in our sample, therefore, though they are included in the descriptive statistics, they were not included in median survival or regression analysis.
Because we suspected trends might be different in areas with higher KS incidence rates, but did not possess sufficient power to compare each SEER area separately, we conducted additional analysis to contrast trends between San Francisco (SF) (3) and all other SEER areas. The number of people in the lowest SES and highest SES category were small in some of the strata. Thus, we collapsed the SES variable into two categories for the Cox models (<10% of county residence in poverty and 10%+ of county residence in poverty).
Results
Pre-HAART (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) , the distribution of sex, extent of disease, age, marital status and ecologic SES differed according to race ( 
Discussion
The study results illustrate that there has been an increase in KS survival in the HAART era. Though survival improved for both black and white men with KS after the introduction of HAART, the degree of improvement was greater for white men on both the relative and absolute scales. This pattern remained after accounting for tumor prognosis.
The increase of a survival disparity is noteworthy, particularly because one of the United
States' health goals during the time of its emergence was specifically to decrease racial disparities in health (18, 19) .
Before the advent of HAART, treatment for Kaposis's sarcoma was largely palliative (20) . HAART, which promotes immune reconstitution, has been shown to cause regression of KS (6, 7) and is recommended either in part or in total as treatment for most KS cases (8, 9) . Thus, increases in its availability and use are likely strong mechanisms through which KS survival has improved. In a recent study of Medicaid insured individuals from 5 states, it was reported that black HIV/AIDS patients were less likely to receive HAART treatment than white patients with HIV/AIDS (21).
Accordingly, one possible explanation for the increase in KS survival disparities in the HAART-era is that there exist differences in the type and quality of treatment afforded to black patients in comparison to white patients.
There are several other possible explanations for the increased KS survival disparity after the advent of HAART. Initial treatment for KS with HAART is one influence on survival: however, long-term adherence to treatment may also be necessary (22) . Thus, differences in treatment adherence may also partially explain differences in survival. Though HAART is an essential treatment for KS, advanced KS often additionally requires other treatments, such as chemotherapy or radiation (9, 23) . Thus some of the increase in disparities may be due to differences in the receipt of these treatments as well.
Additionally, though we were able to account for tumor risk, we were not able to adjust by immune status or HIV-associated systemic diseases using SEER data. Therefore, there could be residual confounding of our findings by these factors.
It is interesting to note that survival disparities existed among those with poor tumor prognosis pre-HAART, though they were relatively small on an absolute scale in There are several potential limitations to the current study. First, the data lack information on treatment with HAART. This hinders our ability to make the direct link between treatment and increased survival. However, the decrease in mortality after the introduction of HAART was dramatic to the extent that much of the trend is likely due to its availability. The literature on health disparities has documented that inequalities are dynamic and their magnitude can change over time. Using empirical data, researchers have shown that after the introduction of a medical innovation benefits tend to be apparent first in more advantaged groups, who have better access to care, and health disparities tend to widen.
Over time as innovations reach less advantaged social strata, health disparities tend to narrow (34). However, it is not inevitable that medical innovations should lead to the emergence of disparities. Improving equal access to efficacious therapy has the potential (at least in theory) to eliminate this source of inequality.
The current data illustrate increasing KS survival disparities after the introduction of HAART, and time will tell if predicted decreases in disparities will be observed in the future. However, it is striking that after 10 years of data follow-up, black patients have yet to achieve the same level of median survival as white patients achieved in just the first year after HAART became available, especially since baseline median survival rates differed by only a few months.
In the case of disparities in infant mortality, which are influenced by the interplay between unequal social conditions and access to advances in medical care, it has been argued that an essential determinant of the relative contributions of underlying risk and health care access is the efficacy of available interventions (35). To a certain extent, this seems also to be case for KS survival. Before efficacious treatment was available, the results of the current study suggest, KS mortality was influenced more by underlying risk than by access to medical care, though access to treatment for other opportunistic infections likely played a role. After the introduction of HAART, the contribution that
The current analysis provides evidence that, in addition to previously reported reductions in KS incidence, there have also been increases in KS survival in the HAARTera. It will take several more years of follow-up data in order to assess just how much median survival in white men has improved since HAART. However, black men have not 
